Cerecor Inc (NASDAQ:CERC) major shareholder Armistice Capital Master Fund bought 25,797 shares of the business’s stock in a transaction on Tuesday, December 4th. The stock was purchased at an average cost of $3.49 per share, with a total value of $90,031.53. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Thursday, November 29th, Armistice Capital Master Fund bought 77,803 shares of Cerecor stock. The stock was purchased at an average cost of $3.51 per share, with a total value of $273,088.53.
  • On Monday, November 26th, Armistice Capital Master Fund bought 50,000 shares of Cerecor stock. The stock was purchased at an average cost of $3.59 per share, with a total value of $179,500.00.
  • On Tuesday, November 20th, Armistice Capital Master Fund bought 49,100 shares of Cerecor stock. The stock was purchased at an average cost of $3.61 per share, with a total value of $177,251.00.
  • On Thursday, November 15th, Armistice Capital Master Fund bought 31,314 shares of Cerecor stock. The stock was purchased at an average cost of $3.85 per share, with a total value of $120,558.90.
  • On Wednesday, October 31st, Armistice Capital Master Fund bought 5,986 shares of Cerecor stock. The stock was purchased at an average cost of $3.92 per share, with a total value of $23,465.12.
  • On Monday, October 29th, Armistice Capital Master Fund bought 107,800 shares of Cerecor stock. The stock was purchased at an average cost of $3.95 per share, with a total value of $425,810.00.
  • On Wednesday, October 24th, Armistice Capital Master Fund bought 125,800 shares of Cerecor stock. The stock was purchased at an average cost of $4.13 per share, with a total value of $519,554.00.
  • On Tuesday, October 9th, Armistice Capital Master Fund bought 29,600 shares of Cerecor stock. The stock was purchased at an average cost of $4.34 per share, with a total value of $128,464.00.
  • On Thursday, September 27th, Armistice Capital Master Fund bought 20,400 shares of Cerecor stock. The stock was purchased at an average cost of $4.64 per share, with a total value of $94,656.00.

NASDAQ:CERC opened at $3.41 on Thursday. The company has a market cap of $139.15 million, a PE ratio of 8.12 and a beta of 1.40. Cerecor Inc has a fifty-two week low of $1.42 and a fifty-two week high of $5.74. The company has a quick ratio of 0.70, a current ratio of 0.74 and a debt-to-equity ratio of 0.74.

Several analysts have issued reports on the company. TheStreet raised Cerecor from a “d” rating to a “c” rating in a research note on Monday, November 12th. ValuEngine raised Cerecor from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of Cerecor by 630.4% during the second quarter. BlackRock Inc. now owns 27,520 shares of the company’s stock valued at $120,000 after purchasing an additional 23,752 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Cerecor during the third quarter valued at approximately $169,000. Finally, Spark Investment Management LLC purchased a new stake in shares of Cerecor during the second quarter valued at approximately $288,000. 44.48% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/cerecor-inc-cerc-major-shareholder-armistice-capital-master-fund-acquires-25797-shares/2664788.html.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.

Featured Story: Why investors pay attention to retained earnings

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.